结构化患者准备方案可抑制心脏结节病PET显像中的生理性18F-FDG心肌摄取
本研究为单中心研究,比较了结构化患者准备方案实施前后行心肌PET检测心脏结节病的患者。实施结构化方案后,生理性心肌18F-FDG摄取抑制率从78%提高至91%(P<.001),弥漫性心肌摄取模式从12%降至2%(P<.001)。结论认为结构化准备方案能高效实现生理性心肌18F-FDG摄取的抑制。
要点
- 结构化准备方案使心肌18F-FDG摄取抑制率从78%升至91%(P<.001)。
- 弥漫性心肌摄取(抑制不充分)从12%降至2%(P<.001)。
- 该方案依据SNMMI/ASNC专家共识推荐,包括高脂低碳饮食和充分禁食。
核心结论
- 结构化患者准备方案在心脏结节病心肌PET中高度成功地抑制了生理性心肌18F-FDG摄取。
研究设计与样本
- 单中心研究,纳入实施新准备方案前(组1)和实施后(组2)所有因心脏结节病行PET扫描的独特患者。
- 组1接受高脂低碳餐食建议及示例,组2接受详细饮食指导、可接受与不可接受餐食示例、护理人员强化指导及饮食日志审核。
主要发现
- 组1纳入124例独特患者,组2纳入232例独特患者,两组基线特征无显著差异。
- 组2生理性心肌18F-FDG摄取抑制率为91%,组1为78%(P<.001)。
- 提示抑制不充分的「弥漫性」心肌摄取模式在组2为2%,组1为12%(P<.001)。
关键数值与推荐
- SNMMI/ASNC准备方案推荐:测试前一天至少两餐高脂(>35g)、低碳水化合物(<3g)饮食,随后禁食至少4-12小时。
临床怎么用
- 对行心肌PET检测心脏结节病的患者,应采用结构化准备方案,包括详细饮食指导、餐食示例、护理强化和饮食日志审核,以提高生理性心肌18F-FDG摄取抑制率。
局限性
- 本研究为单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Myocardial positron emission tomography (PET) to detect cardiac sarcoidosis requires adequate patient preparation; however, in many cases physiologic myocardial 18F-fluorodeoxyglucose (18F-FDG) uptake may not be adequately suppressed. We sought to evaluate the efficacy of a structured patient preparation protocol as recommended by the joint SNMMI/ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. The SNMMI/ASNC preparation protocol recommends at least two high-fat (> 35 g), low-carbohydrate (< 3 g) (HFLC) meals the day before testing followed by fasting for at least 4-12 hours. METHODS: All unique PET scans performed for cardiac sarcoidosis before (group 1) and after (group 2) application of the new preparation protocol were included in the study. In group 1, patients were given a preparation protocol of HFLC meals with suggested meals examples, while patients in group 2 received detailed diet instructions, together with accepted and non-accepted meal examples along. In group 2, reinforcement of instructions by nursing staff and review of dietary log were performed prior to testing. All PET images were evaluated for suppression of physiologic myocardial 18F-FDG uptake. RESULTS: Group 1 included 124 unique patients, and group 2 included 232 unique patients. There were no significant differences in baseline patient characteristics between the two groups. Suppression of physiologic myocardial 18F-FDG uptake was achieved in 91% of patients in group 2, compared to 78% of patients in group 1 (P < .001). A "diffuse" myocardial uptake pattern, indicating inadequate 18F-FDG suppression, was seen in 2% of studies in group 2 vs 12% in group 1 (P < .001). CONCLUSION: In this single-center study, application of a structured preparation protocol was highly successful in achieving suppression of physiologic myocardial 18F-FDG uptake in patients undergoing myocardial PET for cardiac sarcoidosis.
引用
- Christopoulos G, Jouni H, Acharya GA, et al. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol. J Nucl Cardiol. 2019. PMID: 31111450. doi:10.1007/s12350-019-01746-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。